$SLDB

first mention in our archive Sep 8, 2025 · latest 2w ago

Mention stats

Mentions (12mo)

↑ 0%

30d (1 vs 1)

Voices mentioning

↑ 0%

30d (1 vs 1)

Price · Mention timeline

6 mentions since Sep 2025

Loading price chart…

Who's mentioning $SLDB

@adamfeuerstein6

Recent mentions

6 mentions

@adamfeuersteinMay 14, 2026 · 12:48 PM

@pemulisking Approval standard is the biggest overhang, I think. $RGNX single-arm study using correlative analysis to link microD expression to muscle benefit vs $SLDB going with a placebo controlled study to do the same.

Open on X →

@adamfeuersteinApr 16, 2026 · 1:40 PM

@bradloncar Funny how you never see the videos of kids who can't walk up stairs or get up from the floor after taking a gene therapy. Sure, videos like the one shared by $SLDB and previously by

$SRPT

are heartwarming and encouraging, but they are not data.

Open on X →

@adamfeuersteinFeb 18, 2026 · 5:07 PM

"Prasad" stocks today: $CAPR +11%, $REPL +11%, $QURE +9%. $RGNX $SLDB up, too

Open on X →

@adamfeuersteinJan 12, 2026 · 5:07 PM

$SRPT Elevidys Q4 sales $110M vs consensus $120M At his #JPM26 presentation, CEO Doug Ingram notes 80% of addressable ambulatory DMD patients remain untreated. He sees this a huge opportunity for Elevidys, but I will note it's also the same for $SLDB and $RGNX and others developing next-gen gene therapies.

Open on X →

@adamfeuersteinOct 8, 2025 · 4:06 PM

Duchenne gene therapy stocks today: $SLDB +22% $RGNX +14% $SRPT +1%

Open on X →

@adamfeuersteinSep 8, 2025 · 8:25 PM

@bio_clouseau @MauriceOnTW I will get more info and confirm, but I believe $SLDB has said previously that it planned a randomized ex-US study.

Open on X →